MedElevator
Войти в исследования Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
Effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE): a systematic review and meta-analysis of randomized controlled trials.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Ang-Jun, Wu Po-Chang, Chen Yu-Pei, Chu Hsueh-Ting, Chang Hen-Hong
Аннотация
BACKGROUND: Curcumin and Curcuma longa extract have been proposed as adjunct therapies for autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) due to their anti-inflammatory and immunomodulatory properties. The purpose of this study was to determine the effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with RA and SLE.
METHODS: PubMed, EMBASE, and Cochrane CENTRAL databases were searched to May 14, 2025. Randomized controlled trials (RCTs) comparing curcumin or Curcuma longa extract with placebo or standard therapy in patients with RA or SLE were included. The primary outcomes were changes in disease activity score (DAS-28), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level analyzed using standardized mean differences (SMDs) with a random-effects model. Heterogeneity was assessed using the I2 statistic, and sensitivity analyses were conducted using a leave-one-out approach.
RESULTS: Seven RCTs involving 314 patients were included. The meta-analysis revealed no significant effect of curcumin or Curcuma longa extract on DAS-28 (pooled SMD = - 2.34, 95% confidence level [CI]: - 5.13 to 0.44; I2 = 96.0%), ESR (pooled SMD = - 1.49, 95% CI - 3.71 to 0.72; I2 = 91.7%), or CRP (pooled SMD = - 1.65, 95% CI - 3.88 to 0.58; I2 = 91.6%). Substantial heterogeneity was observed across all outcomes.
CONCLUSIONS: This meta-analysis suggests that curcumin and Curcuma longa extract have limited and inconsistent effects on inflammatory biomarkers in patients with RA and SLE. Larger, well-designed RCTs are needed to clarify their clinical utility as adjunct therapies.
METHODS: PubMed, EMBASE, and Cochrane CENTRAL databases were searched to May 14, 2025. Randomized controlled trials (RCTs) comparing curcumin or Curcuma longa extract with placebo or standard therapy in patients with RA or SLE were included. The primary outcomes were changes in disease activity score (DAS-28), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level analyzed using standardized mean differences (SMDs) with a random-effects model. Heterogeneity was assessed using the I2 statistic, and sensitivity analyses were conducted using a leave-one-out approach.
RESULTS: Seven RCTs involving 314 patients were included. The meta-analysis revealed no significant effect of curcumin or Curcuma longa extract on DAS-28 (pooled SMD = - 2.34, 95% confidence level [CI]: - 5.13 to 0.44; I2 = 96.0%), ESR (pooled SMD = - 1.49, 95% CI - 3.71 to 0.72; I2 = 91.7%), or CRP (pooled SMD = - 1.65, 95% CI - 3.88 to 0.58; I2 = 91.6%). Substantial heterogeneity was observed across all outcomes.
CONCLUSIONS: This meta-analysis suggests that curcumin and Curcuma longa extract have limited and inconsistent effects on inflammatory biomarkers in patients with RA and SLE. Larger, well-designed RCTs are needed to clarify their clinical utility as adjunct therapies.